Fig. 4
From: Mesenchymal stem cell-based Smad7 gene therapy for experimental liver cirrhosis
Downregulation of TGF-β1, TGFBR1 and α-SMA after Smad7-MSC treatment. Real-time PCR detection of TGF-β1 (a), TGFBR1 (b) and α-SMA (c) expression in the rat liver tissues treated with Smad7-MSCs, comparing with the control (vehicle), cirrhosis group (with CCl4 injection) and the cirrhosis group treated with MSCs (n = 6 for each group). The GAPDH was set as the housekeeping gene for relative quantification (n = 6 for each group). **P < 0.01 or ***P < 0.001 comparing with the control group; ###P < 0.001 comparing with the cirrhosis group